Chemistry:Maritupirdine

From HandWiki

Maritupirdine (developmental code name AVN-101), a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.[1][2][3] As of November 2013, it was in phase II clinical trials for these indications.[2][3][4][needs update]

It was approved in Russia on May 31, 2023 under the brand name Aviandr for the treatment of generalized anxiety disorder, mild-to-moderate anxiety conditions (stress reactions and adjustment disorders) and anxiety after COVID-19.[5]

See also

References

  1. ↑ "Small Molecule 5-HT6R Ligands: A Comprehensive Insight into their Selectivity and Activity". Current Bioactive Compounds 9 (1): 64–100. 2013. doi:10.2174/1573407211309010007. ISSN 1573-4072. 
  2. ↑ 2.0 2.1 "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews. Drug Discovery 12 (9): 667–87. September 2013. doi:10.1038/nrd4075. PMID 23989795. 
  3. ↑ 3.0 3.1 "Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease". Journal of Medicinal Chemistry 57 (17): 7160–81. September 2014. doi:10.1021/jm5003952. PMID 24850589. 
  4. ↑ "AVN 101". AdisInsight. http://adisinsight.springer.com/drugs/800030006. 
  5. ↑ "Aviandr (2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-bindole hydrochloride) film-coated tablets. Full prescribing information."] (in ru). Avineuro Pharmaceuticals, Inc.. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d3c2176e-3cb9-4ce1-a7f3-ff66abe91bce. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Maritupirdine&oldid=4036821"